Recommendations for antibacterial therapy in adults with COVID-19 – An evidence based guideline

  05 October 2020

The Dutch Working Party on Antibiotic Policy constituted a multidisciplinary expert committee to provide evidence-based recommendation for the use of antibacterial therapy in hospitalized adults with a respiratory infection and suspected or proven 2019 Coronavirus disease (COVID-19).

The 2019 Coronavirus (COVID-19) pandemic due to the novel SARS Coronavirus (SARS-CoV-2) has resulted in a sudden, large and prolonged increase in hospitalizations of patients fulfilling the criteria for community-acquired pneumonia (CAP). SARS-CoV-2 can lead to a wide spectrum of disease, ranging from very mild symptoms of upper respiratory tract infection to life-threatening pneumonia. Severe disease is frequently associated with high inflammation marker levels. It is therefore challenging to define if a patient fulfilling criteria for CAP who is positive for SARS-CoV-2 has a bacterial co-infection upon admission. During hospitalization it may be difficult to distinguish between severe COVID-19 and bacterial secondary infections.

Author(s): Elske Sieswerda, Mark G.J. De Boer, Marc M.J. Bonten, Wim G. Boersma, René E. Jonkers, Roel M. Aleva, Bart-Jan Kullberg, Jeroen A. Schouten, Ewoudt M.W. van de Garde, Theo J. Verheij, Menno M. van der Eerden, Jan M. Prins, W. Joost Wiersinga
Effective Surveillance   Healthy Patients  


Unrestricted financial support by:


Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre


Global Ambassador Network

Welcome at the AMR Insights Ambassador Network!

The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).

More information and free-of-charge registration
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!